Yamamoto M, Akatsu T, Nagase T, Ogata E
Third Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
J Clin Endocrinol Metab. 2000 Dec;85(12):4583-91. doi: 10.1210/jcem.85.12.7035.
Gain-of-function mutations in the calcium ion-sensing receptor (CaR) cause hypocalcemia with low PTH levels. It is stated that patients with activating CaR mutations generally show milder degree of hypocalcemia before treatment and more profound hypercalciuria during treatment than those with idiopathic hypoparathyroidism (IHP). To test this validity we analyzed the data of serum and urinary calcium collected from 85 patients with IHP and 15 with activating CaR mutations. The mean (+/-SEM) serum calcium concentration before treatment was significantly higher (P: < 0.001) in patients with activating CaR mutations (1.76 +/- 0.05 mmol/L; n = 15) than in those with IHP (1.41 +/- 0.03; n = 58), but there was a substantial overlap in the range of hypocalcemia between the two groups (1.25-2. 05 vs. 0.90-1.95). The mean urinary calcium/creatinine ratio (Ca/Cr) in patients with activating CaR mutations before treatment (0.362 +/- 0.045 mmol/mmol; n = 9) was almost equal to that in normocalcemic controls (0.331 +/- 0.022; n = 56) and markedly higher (P: < 0.001) than in patients with IHP (0.093 +/- 0.008; n = 57). The overlap of pretreatment urinary Ca/Cr between the 2 disorders was relatively small; subnormal urinary Ca/Cr was observed in only 1 of 9 patients with CaR mutations and in the majority (49 of 57) of patients with IHP. In contrast to pretreatment findings, the degree of hypercalciuria during treatment was not different between the 2 disorders. The data points of urinary Ca/Cr plotted as a function of the serum calcium concentration were not separable between patients with CaR mutations (n = 8) and those with IHP (n = 40). Comparison of urinary Ca/Cr between 2 patients with a CaR mutation and 7 with IHP over a wide range of serum calcium concentrations measured during 4-8 yr of treatment also indicated that the 2 disorders were inseparable. These results suggested that inappropriately normal urinary Ca/Cr in patients with untreated hypocalcemia, mostly of mild degree, might be a better biochemical clue than the development of severe hypercalciuria during treatment to suspect gain-of-function mutations in the CaR.
钙离子敏感受体(CaR)的功能获得性突变可导致低钙血症伴甲状旁腺激素(PTH)水平降低。据称,与特发性甲状旁腺功能减退症(IHP)患者相比,具有激活型CaR突变的患者在治疗前通常表现出程度较轻的低钙血症,而在治疗期间表现出更严重的高钙尿症。为验证这一说法,我们分析了从85例IHP患者和15例具有激活型CaR突变的患者收集的血清和尿钙数据。具有激活型CaR突变的患者(1.76±0.05 mmol/L;n = 15)治疗前的平均(±标准误)血清钙浓度显著高于IHP患者(1.41±0.03;n = 58)(P:<0.001),但两组低钙血症范围存在大量重叠(1.25 - 2.05 vs. 0.90 - 1.95)。具有激活型CaR突变的患者治疗前的平均尿钙/肌酐比值(Ca/Cr)(0.362±0.045 mmol/mmol;n = 9)几乎与血钙正常的对照组(0.331±0.022;n = 56)相等,且显著高于IHP患者(0.093±0.008;n = 57)(P:<0.001)。两种疾病治疗前尿Ca/Cr的重叠相对较小;在9例CaR突变患者中仅1例观察到尿Ca/Cr低于正常,而在大多数IHP患者(57例中的49例)中观察到尿Ca/Cr低于正常。与治疗前结果相反,两种疾病在治疗期间的高钙尿症程度并无差异。将尿Ca/Cr数据点作为血清钙浓度函数绘制时,CaR突变患者(n = 8)和IHP患者(n = 40)的数据点无法区分。对2例CaR突变患者和7例IHP患者在4 - 8年治疗期间所测的广泛血清钙浓度范围内的尿Ca/Cr进行比较,也表明这两种疾病无法区分。这些结果表明,对于未经治疗的低钙血症患者,大多程度较轻,其尿Ca/Cr异常正常可能是比治疗期间出现严重高钙尿症更好的生化线索,以怀疑CaR存在功能获得性突变。